Luspatercept in patients with lower-risk myelodysplastic syndromes
Patients with anemia and lower-risk myelodysplastic syndromes in whom erythropoiesis-stimulating agent therapy is not effective generally become dependent on red-cell transfusions. Luspatercept, a recombinant fusion protein that binds transforming growth factor β superfamily ligands to reduce SMAD2 and SMAD3 signaling, showed promising results in a phase 2 study.
In a double-blind, placebo-controlled, phase 3 ...
- Publication status:
- Peer review status:
- Peer reviewed
- Pubs id:
- Local pid:
- Deposit date:
- Copyright holder:
- Massachusetts Medical Society
- Copyright date:
- Rights statement:
- © Massachusetts Medical Society 2019.
- This is the publisher's version of the paper. The final version is available online from the Massachusetts Medical Society at: https://doi.org/10.1056/NEJMoa1908892
If you are the owner of this record, you can report an update to it here: Report update to this record